<DOC>
	<DOCNO>NCT01664247</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe North America . The purpose trial investigate effect insulin degludec ( IDeg ) combination liraglutide ( Lira ) metformin ( least 1500 mg daily maximum tolerate dose ) subject type 2 diabetes qualify treatment intensification .</brief_summary>
	<brief_title>The Effect Insulin Degludec Combination With Liraglutide Metformin Subjects With Type 2 Diabetes Qualifying Treatment Intensification</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Insulin na√Øve Ongoing treatment metformin metformin combination either sulphonylurea ( SU ) , glinides , dipeptidyl peptidaseIV ( DPPIV ) inhibitor exenatide ( twice daily ( BID ) ) Glycosylated haemoglobin ( HbA1c ) ( central laboratory analysis ) : . 7.510.0 % ( inclusive ) subject metformin monotherapy , b . 7.09.0 % ( inclusive ) subject metformin combination either SU , glinides , DPPIV inhibitor exenatide ( BID ) Treatment glucoselowering agent ( ) state inclusion criterion within 12 week Calcitonin equal 50 pg/mL Stroke ; heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty ; within 24 week Current past ( within last 5 year ) malignant neoplasm ( except basal cell squamous cell carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>